RecruitingPhase 3NCT04381936

Randomised Evaluation of COVID-19 Therapy

Studying Severe acute respiratory syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Oxford
Principal Investigator
Peter W Horby
University of Oxford
Intervention
Lopinavir-Ritonavir(drug)
Enrollment
70000 target
Eligibility
0 years · All sexes
Timeline
20202036

Study locations (7)

Collaborators

UK Research and Innovation · National Institute for Health Research, United Kingdom · Wellcome Trust · Bill and Melinda Gates Foundation · Department for International Development, United Kingdom · Health Data Research UK · Medical Research Council Population Health Research Unit · NIHR Health Protection Research Unit in Emerging and Zoonotic Infections · Flu Lab

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04381936 on ClinicalTrials.gov

Other trials for Severe acute respiratory syndrome

Additional recruiting or active studies for the same condition.

See all trials for Severe acute respiratory syndrome

← Back to all trials